Akums enters into a joint association with Leiutis and Biophore for introducing first-of-its-kind therapeutics

By: India Pharma Outlook Team | Thursday, 01 December 2022

 India Pharma Outlook Team
o leverage the research expertise and combined manufacturing capacities to introduce first-of-its-kind products in India, Akums Drugs & Pharmaceuticals Ltd, has partnered with Leiutis Pharmaceuticals LLP and Biophore India Pharmaceuticals for research and development of a range of products for multiple therapies. This association is set to bring succour in therapy areas of CNS disorders, Pain management, and Hormonal disorders, where there is a gap in meeting the needs of patients in an effective, safe, and convenient manner. This partnership leverages the strengths of each of the companies resulting in an innovation strategy creating a unique value proposition to doctors and patients in India.

Akums Drugs & Pharmaceuticals currently manufactures around 12% of the country’s total medicinal requirements in the country. The organization deals in the manufacturing and export of formulations in a wide spectrum of dosage forms & therapeutic segments. Akums has emerged as an integrated solution provider for companies seeking solutions around formulations manufacturing and advanced solutions for formulation development and testing.

Akums with reach to different markets, operates 15 fully-certified, state-of-the-art manufacturing facilities across the country. This is coupled with the company's expertise in manufacturing and commercializing virtually all types of formulations, such as tablets, capsules, oral liquids, injections, creams, ointments, etc.; this combines with LEIUTIS Pharmaceuticals LLP, which is a pharmaceutical product innovation company that creates innovative products that advance treatment in specific therapeutic areas. The company rides on proven expertise in Nanotherapeutics, a formidable R&D ecosystem, and a track record of innovation which supports the next generation of speciality medicines.

The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets and with the first few products expected to be commercialised in the next two years. The agreement was signed at the CPHI event and exhibition on the 30th of November 2022 at Greater Noida in the presence of Prof(Dr). Y.K Gupta, President AIIMS Bhopal & President AIIMS Jammu & Former Dean & HoD Pharmacology, AIIMS Delhi.

© 2023 India Pharma Outlook. All Rights Reserved.